In one word,h ow would you describe your research?
"Transfer". As there is no stable nuclide of radium known, the main task of our research is focused on the development of chelating systemsf or barium and the transfer of these systems to the stable complexation of radium due to their similar chemicalp roperties for preparation of a-therapeutics.T his is based on the synthesis of suitable functionalized calix[4]-crowns, which serve as chelator for theseh eavy group 2 metals.
What are the main challengesi nthe broad area of your research?
We are confrontedw ith two types of constraints. The first is related to al acko fs uitable "cages" for the insertion of heavy group 2m etals, because of the coordinationc hemistry.T he second originates from the strong recoil of during the alpha decay,w hich is highera st he energy value of chemical bonds. This leads to the development of "cages", which stably bind the metal ion without ar elease of the ion from this cage. Otherwise, the radium would not reach the desired tumor tissue and accumulate in the bones as classical "bone seeker" due to its chemical nature.
Furthermore,s yntheses with a-emitting radionuclides are challenging, owing to time and mass restrictions (nanomolar synthesis scale).M oreover,a sh ighl evels of radioactivity are manipulated, the automation of radiolabeling procedures is obligatory.C onsequently, radiochemicalm ethodsw ith radium are still rather rare in comparison to the chemistry of the remainingg roup 2m etals used in conventional complex chemistry.
What other topicsare you working on at the moment?
Other projects are also associated with the formation of diagnostic and therapeutic radiotracers.O nt he one hand, we are using nanoparticles like polyoxometalates to stably bind radiometals. These particles will be furtherf unctionalized and serve as transporters for the radionuclides. On the other hand, we are using bioorthogonal methodsl ike the tracelessS taudinger Ligation or the copper-catalyzed click chemistryt oc onnectt he radionuclide to the biologically or pharmacologically active compound under mild andp hysiological conditions.
Invited for this month'sc over picture is the group aroundD r. Constantin Mamata tt he Institute of Radiopharmaceutical CancerR esearch at the Helmholtz-Zentrum Dresden-Rossendorf (Germany) together with Prof. Martin Kçckerling from the University of Rostock( Germany). The cover pictures hows the ability of special functionalized calix[4]crown-6 derivatives to stably bind group 2m etals like barium. This bindingm ode is highlyi mportant for radiopharmaceutical applications not to lose the respective radiometali nv ivo to avoid high backgrounds ignals and/or false positiver esults and damages in other tissues.For this purpose, differentc alix[4]crownswere tested, based upon their potential to stably bind barium as surrogate for radium.R adium nuclides are known to be good candidates for usage in a-targeted therapies. Currently,r adium-223 is used for a-therapy of bone metastases because of its calcium mimetics. Our aim is to apply the radium to treat other cancer tissues.T hat's why we need novel chelators to stably fix groups2metals like barium and radium. Read the full text of their Full Paper at 10.1002/open.201800019.
